Anal Cancer Clinical Trials 2023

Browse 38 Anal Cancer Medical Studies Across 198 Cities

5 Phase 3 Trial · 451 Anal Cancer Clinics

Clinical TrialsAnal Cancer Clinical Trials 2023
Reviewed by Michael Gill, B. Sc.
10 Anal Cancer Clinical Trials Near Me
Top Hospitals for Anal Cancer Clinical Trials
Image of Kingman Regional Medical Center in Arizona.
Kingman Regional Medical Center
Kingman
3Active Trials
3All Time Trials for Anal Cancer
2018First Anal Cancer Trial
Image of University of California, San Francisco in California.
University of California, San Francisco
San Francisco
3Active Trials
4All Time Trials for Anal Cancer
2008First Anal Cancer Trial
Image of National Institutes of Health Clinical Center in Maryland.
National Institutes of Health Clinical Center
Bethesda
3Active Trials
5All Time Trials for Anal Cancer
2018First Anal Cancer Trial
Image of Cross Cancer Institute in Alberta.
Cross Cancer Institute
Edmonton
2Active Trials
2All Time Trials for Anal Cancer
2018First Anal Cancer Trial
Image of Anchorage Associates in Radiation Medicine in Alaska.
Anchorage Associates in Radiation Medicine
Anchorage
2Active Trials
3All Time Trials for Anal Cancer
2018First Anal Cancer Trial
Top Cities for Anal Cancer Clinical Trials
Image of Los Angeles in California.
Los Angeles
16Active Trials
Kaiser Permanente Los Angeles Medical CenterTop Active Site
Image of Anchorage in Alaska.
Anchorage
15Active Trials
Anchorage Associates in Radiation MedicineTop Active Site
Anal Cancer Clinical Trials by Phase of Trial
N/A Anal Cancer Clinical Trials
10Active Anal Cancer Clinical Trials
10Number of Unique Treatments
14Number of Active Locations
Chemotherapy and Adaptive Radiation Treatment PlanningWomen With Prior HPV for Anal NeoplasiaPractice Self-/Companion ExamsHome-based human papillomavirus (HPV) DNA screeningScreening anal Pap Smear - Negative (75%)Cytology Specimen Collection ProcedureLaboratory Biomarker AnalysisBiospecimen Collection - Cervical
Anal Cancer Clinical Trials by Age Group
18+ Anal Cancer Clinical Trials
38Active Anal Cancer Clinical Trials
Discontinue PD-1/PD-L1-1 inhibitor9-valent HPV vaccinationConcurrent Radiation Therapy, 5FU, Mitomycin and BMX-001Valproic AcidNivolumabProton therapypembrolizumabHPV Specific T Cells
Most Recent Anal Cancer Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Reduced Elective Dose + Concurrent Capecitabine/Mitomycin C for Anal Cancer
8/14/2023
Phase 2 & 3
Chemotherapy and Adaptive Radiation Treatment Planning for Anal Carcinoma
5/18/2023
N/A
chemo-radiation treatment for Anal Cancer
5/11/2023
Phase 2
E7 TCR-T cells for Throat Cancer
3/7/2023
Phase 2
Single-agent KFA115 for Nasopharyngeal Cancer
10/26/2022
Phase 1
Top Treatments for Anal Cancer Clinical Trials
Treatment Name
Active Anal Cancer Clinical Trials
All Time Trials for Anal Cancer
First Recorded Anal Cancer Trial
Nivolumab
4
4
2015
M7824
2
3
2018
Discontinue PD-1/PD-L1-1 inhibitor
1
1
2019
9-valent HPV vaccination
1
1
2022
Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001
1
1
2017
Recently Completed Studies with FDA Approved Treatments for Anal Cancer
Treatment
Year
Sponsor
XmAb®22841
2019
Xencor, Inc.
Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
2018
M.D. Anderson Cancer Center
XmAb20717
2018
Xencor, Inc.
M7824
2018
National Cancer Institute (NCI)

What Are Anal Cancer Clinical Trials?

Anal cancer is cancer that occurs in the anus tissues. The majority of anal cancer is caused because of the human papillomavirus (HPV) infection. The primary signs and symptoms of anal cancer include a lump near the anus, rectal bleeding, pain and itching in the anus, mucus discharge, or bowel incontinence.

Why Is Anal Cancer Being Studied Through Clinical Trials?

Anal cancer is rare cancer and less common than rectum or colon cancers. Around 9,440 cases are estimated to occur in 2023, with a higher prevalence among women. The fatalities for anal cancer is 1,670. The lack of treatment options and research is an indication that there is a major need for anal cancer clinical trials and research to find a prevention or cure for this cancer.

What Are The Types of Treatments Available For Anal Cancer?

The treatment for anal cancer might vary depending on the severity and the symptoms experienced by the patient. Generally, anal cancer treatment involves a combination of chemotherapy and radiotherapy, known as chemoradiation.

Some other treatments for anal cancer might include radiotherapy and chemotherapy on their own, surgery, and lifestyle changes.

What Are Some Recent Breakthrough Clinical Trials For Anal Cancer?

2023: The findings of an experimental treatment for rectal cancer are being hailed as a significant breakthrough in recent years. In a small study at Memorial Sloan Kettering, patients were treated with dostarlimab for six months, and the results showed that every patient went into remission. No sign of cancer was found in the MRIs, endoscopies, physical examination, and other scans. In cancer research history, this happened for the first time ever when each participant went into remission after the treatment. This makes way for major interventions and treatment methods for cancer.

2023: The FDA has granted priority review for the combination of Trastuzumab and Tucatinib for treating colorectal cancer among individuals with unresectable or metastatic HER2-positive cancer. This review has been accepted on the basis of the promising results of the Mountaineer phase 2 trial, in which the combination of Trastuzumab and Tucatinib was found to be effective against this cancer compared to the individual dose of both medications. This is a major breakthrough since there are no current FDA-approved treatments or medications for colorectal cancer targeting HER2.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Anal Cancer Clinical Trials Research?

Anal Cancer Foundation: This foundation empowers patients with anal cancer and accelerates the treatment and prevention methods to eliminate cancer, along with the HPV that is responsible for most cases. This is a non-profit, donor-supported advocacy, support, and research organization.

GI Cancers Alliance: This foundation focuses on fighting all gastrointestinal cancers, including anal cancer, by focusing on the voice and needs of the patient to address their unmet needs in treatment, awareness, and screening. The alliance raises awareness and funds to cure, treat and prevent GI cancers.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 14th, 2021

Last Reviewed: August 23rd, 2023

References1 Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853-60. doi: 10.1056/NEJM199803263381301. https://pubmed.ncbi.nlm.nih.gov/95162192 Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853-60. https://pubmed.ncbi.nlm.nih.gov/95162193 de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010 Nov;11(11):1048-56. doi: 10.1016/S1470-2045(10)70230-8. Epub 2010 Oct 15. https://pubmed.ncbi.nlm.nih.gov/209522544 Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3. https://pubmed.ncbi.nlm.nih.gov/309431245 Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf MG, Prins JM. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol. 2013 Apr;14(4):346-53. doi: 10.1016/S1470-2045(13)70067-6. Epub 2013 Mar 15. https://pubmed.ncbi.nlm.nih.gov/234995466 de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menendez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andujar M, Castellsague X, Sanchez GI, Nowakowski AM, Bornstein J, Munoz N, Bosch FX; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010 Nov;11(11):1048-56. doi: 10.1016/S1470-2045(10)70230-8. Epub 2010 Oct 15. https://pubmed.ncbi.nlm.nih.gov/209522547 Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Apr;18(4):446-453. doi: 10.1016/S1470-2045(17)30104-3. Epub 2017 Feb 18. https://pubmed.ncbi.nlm.nih.gov/282230628 Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020 Oct 15;147(8):2190-2198. doi: 10.1002/ijc.33013. Epub 2020 May 2. https://pubmed.ncbi.nlm.nih.gov/323590919 Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, Warner AC, Schweitzer C, Doran SL, Korrapati S, Stevanovic S, Trimble CL, Kanakry JA, Bagheri MH, Ferraro E, Astrow SH, Bot A, Faquin WC, Stroncek D, Gkitsas N, Highfill S, Hinrichs CS. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 2021 Mar;27(3):419-425. doi: 10.1038/s41591-020-01225-1. Epub 2021 Feb 8. https://pubmed.ncbi.nlm.nih.gov/3355872510 Goldstone SE, Hundert JS, Huyett JW. Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males. Dis Colon Rectum. 2007 May;50(5):565-75. https://pubmed.ncbi.nlm.nih.gov/17380365
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top